We are live on ! Find out more
HS

HighVista Strategies Portfolio holdings

AUM $362M
1-Year Est. Return 230.96%
This Fund
S&P 500
This Quarter Est. Return
+7.61%
1 Year Est. Return
+230.96%
3 Year Est. Return
+518.4%
5 Year Est. Return
+644.94%
10 Year Est. Return
+2,223.31%
AUM
$175M
AUM Growth
+$9.44M
Cap. Flow
+$6.42M
Cap. Flow %
3.67%
Top 10 Hldgs %
36.64%
Holding
129
New
19
Increased
30
Reduced
20
Closed
16

Top Buys

Rank Stock Value
1
NLSN
Nielsen Holdings plc
NLSN
+$2.98M
2
BKI
Black Knight, Inc. Common Stock
BKI
+$2.78M
3
VMW
VMware, Inc
VMW
+$2.72M
4
RPTX
Repare Therapeutics
RPTX
+$1.95M
5
COGT icon
Cogent Biosciences
COGT
+$1.63M

Top Sells

Rank Stock Value
1
COHR
Coherent Inc
COHR
+$3.62M
2
TPTX
Turning Point Therapeutics, Inc. Common Stock
TPTX
+$2.96M
3
GBT
Global Blood Therapeutics, Inc.
GBT
+$2.37M
4
IDYA icon
IDEAYA Biosciences
IDYA
+$1.8M
5
DYN icon
Dyne Therapeutics
DYN
+$1.6M

Sector Composition

Rank Sector Weight
1 Healthcare 46.35%
2 Technology 22.42%
3 Financials 15.33%
4 Communication Services 4.08%
5 Consumer Discretionary 3.37%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BEAM icon
76
Beam Therapeutics
BEAM
$2.77B
$600K 0.34%
12,584
-8,396
-40% -$479K
ENTA icon
77
Enanta Pharmaceuticals
ENTA
$393M
$585K 0.33%
+11,286
New +$659K
AMZN icon
78
Amazon
AMZN
$2.94T
$573K 0.33%
5,068
– –
AMRN
79
Amarin Corp
AMRN
$296M
$546K 0.31%
25,034
– –
PCVX icon
80
Vaxcyte
PCVX
$8.81B
$501K 0.29%
20,870
-7,095
-25% -$180K
MORF
81
DELISTED
Morphic Holding, Inc. Common Stock
MORF
$498K 0.28%
17,601
-11,629
-40% -$324K
KRYS icon
82
Krystal Biotech
KRYS
$9.68B
$490K 0.28%
7,035
-5,190
-42% -$375K
RXDX
83
DELISTED
Prometheus Biosciences, Inc. Common Stock
RXDX
$462K 0.26%
7,831
-2,951
-27% -$135K
TERN
84
DELISTED
Terns Pharmaceuticals
TERN
$456K 0.26%
+77,344
New +$287K
PTC icon
85
PTC
PTC
$16.3B
$451K 0.26%
4,310
– –
SWTX
86
DELISTED
SpringWorks Therapeutics
SWTX
$368K 0.21%
12,888
-6,192
-32% -$178K
TMUS icon
87
T-Mobile US
TMUS
$192B
$347K 0.2%
2,588
– –
JD icon
88
JD.com
JD
$43.1B
$344K 0.2%
6,838
+1,740
+34% +$103K
PNT
89
DELISTED
POINT Biopharma Global Inc. Common Stock
PNT
$339K 0.19%
+43,836
New +$372K
INCY icon
90
Incyte
INCY
$24.5B
$336K 0.19%
+5,048
New +$373K
ADSK icon
91
Autodesk
ADSK
$53.1B
$330K 0.19%
1,766
– –
BCRX icon
92
BioCryst Pharmaceuticals
BCRX
$2.64B
$326K 0.19%
+25,837
New +$332K
IMGN
93
DELISTED
Immunogen Inc
IMGN
$311K 0.18%
65,151
-126,575
-66% -$667K
AVTA
94
DELISTED
Avantax, Inc. Common Stock
AVTA
$307K 0.18%
15,872
– –
WTW icon
95
Willis Towers Watson
WTW
$31.8B
$296K 0.17%
1,474
– –
RNAM
96
DELISTED
Avidity Biosciences
RNAM
$283K 0.16%
17,334
-7,530
-30% -$144K
PMVP icon
97
PMV Pharmaceuticals
PMVP
$69.3M
$278K 0.16%
23,324
– –
NOW icon
98
ServiceNow
NOW
$132B
$277K 0.16%
3,660
– –
ALV icon
99
Autoliv
ALV
$8.96B
$261K 0.15%
3,914
– –
WRBY icon
100
Warby Parker
WRBY
$3.1B
$261K 0.15%
19,550
– –
2 3
4
5 6

Similar funds

SIAG
Safeguard Investment Advisory Group Corona, California $362M AUM 20.96% 1-Year Est. Return
MS
Millington Securities Red Bank, New Jersey $362M AUM
WTFG
Wood Tarver Financial Group Boise, Idaho $362M AUM 14.75% 1-Year Est. Return
A6
Anchor @ 65 Singapore $362M AUM 20.02% 1-Year Est. Return
PI
Pennant Investors Summit, New Jersey $361M AUM 134.26% 1-Year Est. Return
ACM
Anfield Capital Management Irvine, California $363M AUM 24.08% 1-Year Est. Return
PPG
Peak Planning Group Centennial, Colorado $361M AUM 22.01% 1-Year Est. Return
PWC
PYA Waltman Capital Knoxville, Tennessee $361M AUM 9.49% 1-Year Est. Return

HighVista Strategies's Q3 2022 Portfolio in Review

As of Q3 2022, HighVista Strategies held 129 positions worth $175M, up 5.7% from $166M the previous quarter. Its ten largest holdings account for 37% of the portfolio.

HighVista Strategies deployed $6.42M of net new capital in Q3 2022, opening 19 new positions and adding to 30 existing holdings. Its largest new stake was Nielsen Holdings plc: 114,200 shares worth $3.17M.

By sector, the portfolio is most concentrated in Healthcare at 46% of assets, down from 46% a quarter earlier, followed by Technology and Financials.

On the sell side, the largest reduction was Dyne Therapeutics, an estimated $1.6M trimmed.

  • HighVista Strategies's largest Q3 2022 buy was Nielsen Holdings plc: 114,200 shares worth $3.17M.
  • HighVista Strategies added most to Repare Therapeutics in Q3 2022, an estimated $1.95M increase.
  • HighVista Strategies's biggest Q3 2022 reduction was Dyne Therapeutics, cutting an estimated $1.6M.
  • HighVista Strategies fully exited Coherent Inc in Q3 2022, selling an estimated $3.62M.
  • HighVista Strategies's ten largest holdings make up 37% of its $175M portfolio in Q3 2022.
  • HighVista Strategies opened 19 new positions and closed 16 in Q3 2022.
  • HighVista Strategies's portfolio value rose 5.7% quarter-over-quarter to $175M.

Based on HighVista Strategies's 13F filing for Q3 2022, filed 14 Nov 2022.